Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 24/5/2020
SIETES contiene 93008 citas

 1 a 20 de 1304 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Anónimo. GSK cuts back operations in Africa. DIA Daily 2018:1. [Ref.ID 102445]
3. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
4. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
6. Cita con resumen
Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ 2016;352:i1284. [Ref.ID 100333]
9.Tiene citas relacionadas Cita con resumen
Kmietowicz Z. NICE rejects trastuzumab emtansine for use on NHS. BMJ 2015;351:h6837. [Ref.ID 99764]
10.Tiene citas relacionadas Cita con resumen
Meier F, Maas R, Sonst A, Patapovas A, Müller F, Plank-Kiegele B, Pfistermeister B, Schöffski O, Bürkle T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 2015;24:176-86. [Ref.ID 99600]
11.Enlace a cita original Cita con resumen
Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]
12. Cita con resumen
Anónimo. Britain’s NHS cuts funding for costly cancer medicines. DIA Daily 2015:13 de enero. [Ref.ID 98704]
13. Cita con resumen
Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial. A modeling study. Ann Intern Med 2014;160:594-602. [Ref.ID 97572]
14. Cita con resumen
Coyne DW. Anemia in chronic kidney disease: treating the numbers, not the patients. JAMA Intern Med 2014;174:708-9. [Ref.ID 97192]
15. Cita con resumen
O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot?. JAMA 2013;310:1343-4. [Ref.ID 96323]
16. Cita con resumen
Erickson KF, Chertow GM, Goldhaber-Fiebert D. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013;159:382-9. [Ref.ID 96107]
17. Cita con resumen
Díez-Manglano J. Análisis económico del tratamiento de la insuficiencia cardiaca con betabloqueantes. Med Clin (Barc) 2013;141:265-70. [Ref.ID 96079]
18. Cita con resumen
Gellad WF, Donohue JM, Zhao X, Mor MK, Thorpe CT, Smith J, Good CB, Fine MJ, Morden NE. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison. Ann Intern Med 2013;159:105-14. [Ref.ID 95864]
19. Cita con resumen
Rawlins M. NICE times: a valedictory dispatch. Lancet 2013;381:2225-7. [Ref.ID 95752]
20. Cita con resumen
Chinthapalli K. NICE is dead; long live NICE. BMJ 2013;346:16. [Ref.ID 95480]
Seleccionar todas
 1 a 20 de 1304 siguiente >>